MarginsXMarginsX
Home › Markets › Health Care › JAGX

Jaguar Health Inc. (JAGX)

JAGX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.3864
-7.74% on the day
Market cap
$5.2M
Nano cap
Revenue · 2025
$11.5M
-1.5% on 2024
Net income · 2025
-$53.6M
-465.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1585608/000119312526144470/0001193125-26-144470-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerJAGX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2015
SEC CIK0001585608
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$11.5M
Net income-$53.6M
Operating income-$45.9M
Net margin-465.4%
Operating margin-398.8%
Revenue growth-1.5%
Cash$968K
Total assets$38.3M
P/E (computed)Net income was not positive
P/S (computed)0.4×

Warning signs

Cash runway
6.8 months
$3.8M cash at June 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
Yes
10-Q filed August 19, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern over the next 12 months after the date these financial statements are issued."
10-Q 2026-08-19
Cash and burn$3.8M cash; operating cash flow -$1.7M a quarter.Report 2026-06-30
Shares outstandingNo cover-page share count in XBRLCover page 2026-07-31
Reverse splits, 3 years4; latest 1-for-15 on 2026-09-17Source 2026-09-17
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-11-09
Exchange deficiency notices, 12 months3 (8-K item 3.01)8-K 2026-05-04
AuditorRBSM LLP, LARKSPUR, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-02-20
Late filings, 12 months3 NT noticesNT 10-Q 2026-08-14
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$1.2M-$12.8M-$5.3M$3.8M$29.4M$27.8M10-Q 2026-08-19
Q1 2026
2026-03-31
$20.3M$8.7M$8.8M$7.3M$55.2M$29.6M10-Q 2026-05-20
Q4 2025
2025-12-31
$3.2M-$23.2M-$5.5M$968K$70.0M$11.5M10-K 2026-04-07
Q3 2025
2025-09-30
$3.1M-$9.5M-$4.7M$3.5M$53.9M$11.8M10-Q 2025-11-14
Q2 2025
2025-06-30
$3.0M-$10.4M-$6.2M$2.2M$47.9M$11.8M10-Q 2026-08-19
Q1 2025
2025-03-31
$2.2M-$10.5M-$7.3M$5.7M$55.7M$11.6M10-Q 2026-05-20
Q4 2024
2024-12-31
$3.5M-$9.9M-$7.8M$8.0M$47.6M$11.7M10-K 2026-04-07
Q3 2024
2024-09-30
$3.1M-$9.9M-$6.3M$13.3M$44.6M$10.5M10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-09
Latest annual report10-K2026-04-07
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-10-29

Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.7%
1 month-89.9%
3 months-96.4%
Year to date-99.9%
1 year-100.0%
From 52-week high-100.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CNSPCNS Pharmaceuticals Inc.$3.48+20.42%$5.1M
CVKDCadrenal Therapeutics Inc.$1.40-7.28%$5.0M
SCNXScienture Holdings Inc.$2.99+3.10%$4.9M
PULMPulmatrix Inc.$1.33+2.31%$4.9M
PCSAProcessa Pharmaceuticals Inc.$1.72-7.53%$4.8M
CANFCan-Fite Biopharma Ltd$1.56+9.86%$4.7M
SKYESkye Bioscience Inc.$1.06-2.29%$4.7M
ACXPAcurx Pharmaceuticals Inc.$0.9350-2.60%$5.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier